NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
15 trialsNCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01824901 2023-06-29
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 1/2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT01791985 2022-08-22
RADICAL
Imperial College London
Phase 1/2 Completed
NCT05086666 2021-10-21
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
Abbisko Therapeutics Co, Ltd
Phase 1/2 Unknown
NCT04439240 2021-06-29
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02965378 2021-05-27
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2/3 Completed
NCT00979134 2019-03-15
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
AstraZeneca
Phase 1 Terminated
NCT01457846 2017-03-07
SHINE
AstraZeneca
Phase 2 Terminated
NCT01213160 2016-06-29
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
AstraZeneca
Phase 1 Completed
NCT01202591 2016-02-11
GLOW
AstraZeneca
Phase 1/2 Completed